Buprenorphine

Major

Buprenorphine Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Buprenorphine Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation and an increased risk of CNS and respiratory depression Details Buprenorphine Aclidinium Oral Inhalation Tudorza An increased risk of paralytic ileus Details Buprenorphine Atropine Ophthalmic Atropine Care 1% An increased risk of paralytic ileus Details Buprenorphine Butorphanol Injection Butorphic Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Butorphanol Nasal Spray Stadol® NS Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Cetirizine Injection Aller-Tec An increased risk of respiratory depression and CNS depression Details Buprenorphine Cetirizine Ophthalmic Zerviate An increased risk of respiratory depression and CNS depression Details Buprenorphine Cyclopentolate Ophthalmic Akpentolate® An increased risk of paralytic ileus Details Buprenorphine Cyclosporine Injection Atopica Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Cyclosporine Ophthalmic Cequa Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Buprenorphine Degarelix Injection Firmagon An increased risk of QT interval prolongation Details Buprenorphine Dexamethasone Injection Decadron Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced buprenorphine exposure and reduced efficacy of buprenorphine Details Buprenorphine Diazepam Nasal Spray Valtoco An increased risk of CNS depression and respiratory depression Details Buprenorphine Diazepam Rectal Diastat An increased risk of CNS depression and respiratory depression Details Buprenorphine Diphenhydramine Injection Banophen An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Diphenhydramine Topical Afterbite with Antihistamine An increased risk of respiratory and CNS depression and an increased risk of paralytic ileus Details Buprenorphine Dolasetron Injection Anzemet An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Eribulin Injection Halaven An increased risk of QT interval prolongation Details Buprenorphine Esketamine Nasal Spray Spravato An increased risk of respiratory depression and CNS depression Details Buprenorphine Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Buprenorphine Fentanyl Transdermal Patch Duragesic® Reduced analgesic effect or precipitation of withdrawal symptoms, and an increased risk of serotonin syndrome Details Buprenorphine Foscarnet Injection Foscavir An increased risk of QT interval prolongation Details Buprenorphine Furosemide Injection Disal Reduced efficacy of diuretics Details Buprenorphine Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Buprenorphine Glycopyrronium Topical Cuvposa® An increased risk of paralytic ileus Details Buprenorphine Goserelin Implant Zoladex An increased risk of QT interval prolongation Details Buprenorphine Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Granisetron Injection Granisol An increased risk of QT interval prolongation and an increased risk of serotonin syndrome Details Buprenorphine Histrelin Implant Supprelin An increased risk of QT interval prolongation Details Buprenorphine Hydromorphone Injection Dilaudid Reduced analgesic effect or precipitation of withdrawal symptoms and an increased risk of serotonin syndrome Details Buprenorphine Hydromorphone Rectal available generically Reduced analgesic effect or precipitation of withdrawal symptoms and an increased risk of serotonin syndrome Details Buprenorphine Inotuzumab Ozogamicin Injection Besponsa An increased risk of QT interval prolongation Details Buprenorphine Ipratropium Nasal Spray Atrovent Nasal Spray® An increased risk of paralytic ileus Details Buprenorphine Ipratropium Oral Inhalation Atrovent® HFA An increased risk of paralytic ileus Details Buprenorphine Lacosamide Injection Motpoly An increased risk of CNS depression Details Buprenorphine Lenacapavir Injection Sunlenca Increased or reduced buprenorphine exposure Details Buprenorphine Lenacapavir Oral Sunlenca Increased or reduced buprenorphine exposure Details Buprenorphine Letermovir Injection Prevymis Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details